{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:20:28Z","timestamp":1790882428936,"version":"4.1.0"},"reference-count":87,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Carbapenem-resistant Acinetobacter baumannii (CRAB) is an emerging and important major cause of nosocomial infections, posing a significant challenge to clinicians worldwide. The intrinsic and acquired resistance mechanisms exhibited by CRAB, associated with its ability to persist in healthcare environments, have transformed it into a critical public health concern. The clinical implications of CRAB infections include severe manifestations, like ventilator-associated pneumonia and bloodstream infections. These infections are often associated with increased morbidity and mortality, particularly in critically ill patients, such as those in intensive care units, immunocompromised, and those undergoing invasive procedures. Considering these characteristics, the therapeutic armamentarium for the treatment of CRAB infections is increasingly limited, as these strains exhibit resistance to a broad range of antibiotics, including carbapenems and the new \u03b2-lactam inhibitors, which are considered last-line agents for many bacterial infections. An important role is represented by cefiderocol and data from real-world evidence. The aim of this narrative review is to discuss the main topics of CRAB infection and strategies for prevention, management, and therapy.<\/jats:p>","DOI":"10.3390\/microorganisms13040829","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T10:47:41Z","timestamp":1744282061000},"page":"829","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The Multifaceted Landscape of Healthcare-Associated Infections Caused by Carbapenem-Resistant Acinetobacter baumannii"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3846-4620","authenticated-orcid":false,"given":"Alessandro","family":"Russo","sequence":"first","affiliation":[{"name":"Infectious and Tropical Disease Unit, Department of Medical and Surgical Sciences, \u2018Magna Graecia\u2019 University of Catanzaro, Viale Europa, 88100 Grosseto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5555-3732","authenticated-orcid":false,"given":"Francesca","family":"Serapide","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Disease Unit, Department of Medical and Surgical Sciences, \u2018Magna Graecia\u2019 University of Catanzaro, Viale Europa, 88100 Grosseto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter baumannii: Emergence of a successful pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/CMR.00058-16","article-title":"Clinical and pathophysiological overview of Acinetobacter infections: A century of challenges","volume":"30","author":"Wong","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrmicro.2017.148","article-title":"Uncovering the mechanisms of Acinetobacter baumannii virulence","volume":"16","author":"Harding","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.1093\/cid\/ciad109","article-title":"Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus Complex","volume":"76","author":"Castanheira","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1093\/cid\/ciad094","article-title":"Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections","volume":"76","author":"Shields","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","unstructured":"Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet, 399, 629\u2013655."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3201\/eid3101.241426","article-title":"Cefiderocol Resistance Conferred by Plasmid-Located Ferric Citrate Transport System in KPC-Producing Klebsiella pneumoniae","volume":"31","author":"Polani","year":"2025","journal-title":"Emerg. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"107321","DOI":"10.1016\/j.ijid.2024.107321","article-title":"Emergence of cefiderocol resistance during therapy in NDM-5-producing Klebsiella pneumoniae isolates harboring siderophore receptors mutations","volume":"151","author":"Deroche","year":"2025","journal-title":"Int. J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Alteri, C., Teri, A., Liporace, M.F., Muscatello, A., Terranova, L., Schianca, M.C., Salari, F., Orena, B.S., Silverj, F.G., and Bernazzani, M. (2024). Transmission cluster of cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii in cefiderocol-na\u00efve individuals. Ann. Clin. Microbiol. Antimicrob., 23.","DOI":"10.1186\/s12941-024-00763-7"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e0075424","DOI":"10.1128\/aac.00754-24","article-title":"Overexpression of \u03b2-lactamase genes (blaKPC,blaSHV) and novel CirA deficiencies contribute to decreased cefiderocol susceptibility in carbapenem-resistant Klebsiella pneumoniae before its approval in China","volume":"68","author":"Hong","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"dlae146","DOI":"10.1093\/jacamr\/dlae146","article-title":"Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections","volume":"6","author":"Shields","year":"2024","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Longshaw, C., Santerre Henriksen, A., Dressel, D., Malysa, M., Silvestri, C., Takemura, M., Yamano, Y., Baba, T., and Slover, C.M. (2023). Heteroresistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: A post hoc analysis. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.02371-23"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/QCO.0000000000000964","article-title":"What is the clinical significance of \u2018heteroresistance\u2019 in nonfermenting Gram-negative strains?","volume":"36","author":"Tiseo","year":"2023","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mezcord, V., Escalante, J., Nishimura, B., Traglia, G.M., Sharma, R., Vall\u00e9, Q., Tuttobene, M.R., Subils, T., Marin, I., and Pasteran, F. (2023). Induced Heteroresistance in Carbapenem-Resistant Acinetobacter baumannii (CRAB) via Exposure to Human Pleural Fluid (HPF) and Its Impact on Cefiderocol Susceptibility. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202306.0950.v1"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Stracquadanio, S., Bonomo, C., Marino, A., Bongiorno, D., Privitera, G.F., Bivona, D.A., Mirabile, A., Bonacci, P.G., and Stefani, S. (2022). Acinetobacter baumannii and Cefiderocol, between Cidality and Adaptability. Microbiol. Spectr., 10.","DOI":"10.1128\/spectrum.02347-22"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin. Infect. Dis., ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"106611","DOI":"10.1016\/j.ijantimicag.2022.106611","article-title":"Diagnosis and management of infections caused by multidrug-resistant bacteria: Guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM)","volume":"60","author":"Tiseo","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e0214221","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"106825","DOI":"10.1016\/j.ijantimicag.2023.106825","article-title":"Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19","volume":"62","author":"Russo","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Dalfino, L., Stufano, M., Bavaro, D.F., Diella, L., Belati, A., Stolfa, S., Romanelli, F., Ronga, L., Di Mussi, R., and Murgolo, F. (2023). Effectiveness of First-Line Therapy with Old and Novel Antibiotics in Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant Acinetobacter baumannii: A Real Life, Prospective, Observational, Single-Center Study. Antibiotics, 12.","DOI":"10.3390\/antibiotics12061048"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","article-title":"Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: A multicentre cohort study","volume":"3","author":"Pascale","year":"2021","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Mazzitelli, M., Gregori, D., Sasset, L., Trevenzoli, M., Scaglione, V., Lo Menzo, S., Marinello, S., Mengato, D., Venturini, F., and Tiberio, I. (2023). Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic. Microorganisms, 11.","DOI":"10.3390\/microorganisms11040984"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"107047","DOI":"10.1016\/j.ijantimicag.2023.107047","article-title":"Clinical efficacy of cefiderocol-based regimens in patients affected by carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis","volume":"63","author":"Gatti","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e0092421","DOI":"10.1128\/AAC.00924-21","article-title":"Extensively Drug-Resistant Acinetobacter baumannii Nosocomial Pneumonia Successfully Treated with a Novel Antibiotic Combination","volume":"65","author":"Zaidan","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lyu, C., Zhang, Y., Liu, X., Wu, J., and Zhang, J. (2020). Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-05026-2"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jgar.2022.08.002","article-title":"Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016\u20132018)","volume":"31","author":"Seifert","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/pharmrev.120.000020","article-title":"Rescuing the Last-Line Polymyxins: Achievements and Challenges","volume":"73","author":"Nang","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijid.2014.10.014","article-title":"An update on the arsenal for multidrug-resistant Acinetobacter infections: Polymyxin antibiotics","volume":"30","author":"Kassamali","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: An open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_33","first-page":"349","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: A multicenter, randomized clinical trial","volume":"3","author":"Signoriello","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1128\/AAC.02435-13","article-title":"Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections","volume":"9","author":"Sirijatuphat","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e01154-19","DOI":"10.1128\/AAC.01154-19","article-title":"In Vitro Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018","volume":"63","author":"Flamm","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e01809-20","DOI":"10.1128\/AAC.01809-20","article-title":"Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN)","volume":"65","author":"Lodise","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13613-020-00715-2","article-title":"Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections","volume":"10","author":"Lisi","year":"2020","journal-title":"Ann. Intensive Care"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s10096-022-04503-7","article-title":"In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii","volume":"41","author":"Ni","year":"2022","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/cid\/ciad435","article-title":"Intravenous fosfomycin: The underdog player in the treatment of carbapenem-resistant Acinetobacter baumannii infections","volume":"77","author":"Guastalegname","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40121-020-00357-8","article-title":"Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii: A Prospective, Observational Study","volume":"10","author":"Russo","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Assimakopoulos, S.F., Karamouzos, V., Eleftheriotis, G., Lagadinou, M., Bartzavali, C., Kolonitsiou, F., Paliogianni, F., Fligou, F., and Marangos, M. (2023). Efficacy of Fosfomycin-Containing Regimens for Treatment of Bacteremia Due to Pan-Drug Resistant Acinetobacter baumannii in Critically Ill Patients: A Case Series Study. Pathogens, 12.","DOI":"10.3390\/pathogens12020286"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/AAC.04808-14","article-title":"Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii","volume":"59","author":"Penwell","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Kuo, S.C., Lee, Y.T., Yang Lauderdale, T.L., Huang, W.C., Chuang, M.F., Chen, C.P., Su, S.C., Lee, K.R., and Chen, T.L. (2015). Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii. Front. Microbiol., 6.","DOI":"10.3389\/fmicb.2015.00231"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Durand-R\u00e9ville, T.F., Guler, S., Comita-Prevoir, J., Chen, B., Bifulco, N., Huynh, H., Lahiri, S., Shapiro, A.B., McLeod, S.M., and Carter, N.M. (2017). ETX2514 is a broad-spectrum \u03b2-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat. Microbiol., 2.","DOI":"10.1038\/nmicrobiol.2017.104"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Principe, L., Di Bella, S., Conti, J., Perilli, M., Piccirilli, A., Mussini, C., and Decorti, G. (2022). Acinetobacter baumannii Resistance to Sulbactam\/Durlobactam: A Systematic Review. Antibiotics, 11.","DOI":"10.3390\/antibiotics11121793"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e01089-18","DOI":"10.1128\/AAC.01089-18","article-title":"Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects","volume":"62","author":"Rodvold","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: A multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/S1473-3099(23)00422-X","article-title":"Sulbactam-durlobactam for infections caused by Acinetobacter baumannii-calcoaceticus complex","volume":"23","author":"Giuliano","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/S1473-3099(23)00423-1","article-title":"Sulbactam-durlobactam for infections caused by Acinetobacter baumannii-calcoaceticus complex\u2014Authors\u2019 reply","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Petropoulou, D., Siopi, M., Vourli, S., and Pournaras, S. (2022). Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece. Front. Cell Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.814530"},{"key":"ref_52","unstructured":"(2025, February 14). National Library of Medicine, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): A randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40265-021-01580-4","article-title":"Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"106882","DOI":"10.1016\/j.ijantimicag.2023.106882","article-title":"Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence","volume":"62","author":"Kollef","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e0199021","DOI":"10.1128\/AAC.01990-21","article-title":"In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e0087721","DOI":"10.1128\/AAC.00877-21","article-title":"Contribution of PER-Type and NDM-Type \u03b2-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii","volume":"65","author":"Poirel","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(21)00194-8","article-title":"Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens","volume":"21","author":"Choby","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Karakonstantis, S., Rousaki, M., and Kritsotakis, E.I. (2022). Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance. Antibiotics, 11.","DOI":"10.3390\/antibiotics11060723"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e01437-20","DOI":"10.1128\/AAC.01437-20","article-title":"Population Pharmacokinetic and Pharmacokinetic\/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection\/Sepsis, or Complicated Urinary Tract Infection","volume":"65","author":"Kawaguchi","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Palombo, M., Bovo, F., Amadesi, S., and Gaibani, P. (2023). Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria. Antibiotics, 12.","DOI":"10.3390\/antibiotics12050858"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Mohd Sazlly Lim, S., Heffernan, A., Naicker, S., Wallis, S., Roberts, J.A., and Sime, F.B. (2022). Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant Acinetobacter baumannii Isolates in a Hollow-Fibre Infection Model. Antibiotics, 11.","DOI":"10.3390\/antibiotics11111578"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ijantimicag.2008.08.023","article-title":"Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: A report from the OPTAMA program","volume":"33","author":"Koomanachai","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Bavaro, D.F., Belati, A., Diella, L., Stufano, M., Romanelli, F., Scalone, L., Stolfa, S., Ronga, L., Maurmo, L., and Dell\u2019Aera, M. (2021). Cefiderocol-Based Combination Therapy for \u201cDifficult-to-Treat\u201d Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives. Antibiotics, 10.","DOI":"10.3390\/antibiotics10060652"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"ofac092","DOI":"10.1093\/ofid\/ofac092","article-title":"Novel Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Necrotizing Pneumonia Complicated by Empyema: A Case Report","volume":"9","author":"Holger","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ki.2010.337","article-title":"New insights into the mechanism of aminoglycoside nephrotoxicity: An integrative point of view","volume":"79","author":"Quiros","year":"2011","journal-title":"Kidney Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/0885066618754784","article-title":"Evaluation of Epithelial Lining Fluid Concentration of Amikacin in Critically Ill Patients With Ventilator-Associated Pneumonia","volume":"35","author":"Najmeddin","year":"2020","journal-title":"J. Intensive Care Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1874285801711010063","article-title":"Synergistic Effect of Colistin and Rifampin Against Multidrug Resistant Acinetobacter baumannii: A Systematic Review and Meta-Analysis","volume":"11","author":"Mohammadi","year":"2017","journal-title":"Open Microbiol. J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijantimicag.2007.07.007","article-title":"Comparative activities of colistin, rifampicin, imipenem and sulbactam\/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases","volume":"30","author":"Tripodi","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"176","DOI":"10.24015\/JAPM.2018.0072","article-title":"Combined Rifampin and Sulbactam Therapy for Multidrug-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia in Pediatric Patients","volume":"5","author":"Chen","year":"2018","journal-title":"J. Anesth. Perioper. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.drudis.2021.07.001","article-title":"Rifabutin for infusion (BV100) for the treatment of severe carbapenem-resistant Acinetobacter baumannii infections","volume":"26","author":"Trebosc","year":"2021","journal-title":"Drug Discov. Today."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijantimicag.2015.04.002","article-title":"Trimethoprim\/sulfamethoxazole for Acinetobacter spp.: A review of current microbiological and clinical evidence","volume":"46","author":"Falagas","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jgar.2018.12.001","article-title":"Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: A retrospective matched cohort study","volume":"17","author":"Liron","year":"2019","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"107190","DOI":"10.1016\/j.ijantimicag.2024.107190","article-title":"Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: A multicenter clinical experience","volume":"64","author":"Russo","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijid.2019.11.006","article-title":"Antimicrobial activity of cefoperazone-sulbactam tested against Gram-Negative organisms from Europe, Asia-Pacific, and Latin America","volume":"91","author":"Sader","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s42770-023-01015-0","article-title":"Oral doxycycline to carbapenem-resistant Acinetobacter baumannii infection as a polymyxin-sparing strategy: Results from a retrospective cohort","volume":"54","author":"Tuon","year":"2023","journal-title":"Braz. J. Microbiol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Serapide, F., Guastalegname, M., Gull\u00ec, S.P., Lionello, R., Bruni, A., Garofalo, E., Longhini, F., Trecarichi, E.M., and Russo, A. (2024). Antibiotic Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections in View of the Newly Developed \u03b2-Lactams: A Narrative Review of the Existing Evidence. Antibiotics, 13.","DOI":"10.20944\/preprints202405.0203.v1"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e2023043","DOI":"10.4084\/MJHID.2023.043","article-title":"In vitro Activity of Cefiderocol Against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Single Center Experience","volume":"15","author":"Quirino","year":"2023","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jinf.2019.05.017","article-title":"Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study","volume":"79","author":"Russo","year":"2019","journal-title":"J. Infect."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ijantimicag.2018.06.018","article-title":"Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"52","author":"Russo","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/14740338.2018.1488962","article-title":"Antimicrobial resistance and treatment: An unmet clinical safety need","volume":"17","author":"Bassetti","year":"2018","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Medioli, F., Bacca, E., Faltoni, M., Burastero, G.J., Volpi, S., Menozzi, M., Orlando, G., Bedini, A., Franceschini, E., and Mussini, C. (2022). Is It Possible to Eradicate Carbapenem-Resistant Acinetobacter baumannii (CRAB) from Endemic Hospitals?. Antibiotics, 11.","DOI":"10.3390\/antibiotics11081015"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13756-021-00990-z","article-title":"A five-component infection control bundle to permanently eliminate a carbapenem-resistant Acinetobacter baumannii spreading in an intensive care unit","volume":"10","author":"Meschiari","year":"2021","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13756-021-00919-6","article-title":"Risk factors for nosocomial rectal colonization with carbapenem-resistant Acinetobacter baumannii in hospital: A matched case-control study","volume":"10","author":"Meschiari","year":"2021","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"ofaa461","DOI":"10.1093\/ofid\/ofaa461","article-title":"Epidemiology and Risk Factors Associated With Mortality in Consecutive Patients With Bacterial Bloodstream Infection: Impact of MDR and XDR Bacteria","volume":"7","author":"Santoro","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhin.2024.04.011","article-title":"Air dispersal of multi-drug-resistant organisms including meticillin-resistant Staphylococcus aureus, carbapenem-resistant Acinetobacter baumannii and carbapenemase-producing Enterobacterales in general wards: Surveillance culture of air grilles","volume":"149","author":"Wong","year":"2024","journal-title":"J. Hosp. Infect."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Viscardi, S., Topola, E., Sobieraj, J., and Duda-Madej, A. (2024). Novel Siderophore Cephalosporin and Combinations of Cephalosporins with \u03b2-Lactamase Inhibitors as an Advancement in Treatment of Ventilator-Associated Pneumonia. Antibiotics, 13.","DOI":"10.3390\/antibiotics13050445"}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/13\/4\/829\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:11:01Z","timestamp":1760029861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/13\/4\/829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":87,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["microorganisms13040829"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms13040829","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]}}}